SignalPath Competitors or Alternatives

SignalPath's top competitors include OpenClinica, Clinical Ink and Medrio.

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

SignalPath's company profile

CEO

- -
100 - 250
$35M
$5M - 25M
1
SignalPath's Competitor - OpenClinica logo

David Kay

CEO

82/100
25 - 100
$350K
$5M - 25M
2
SignalPath's Competitor - Clinical Ink logo

Jonathan Goldman

CEO

62/100
250 - 500
$27.4M
$25M - 100M
3
SignalPath's Competitor - Medrio logo

Nicole DuPont Latimer

CEO

69/100
100 - 250
$34M
$25M - 100M
4
SignalPath's Competitor - Acceliant logo

Sri Manchala

Chairman & CEO

81/100
25 - 100
- -
$5M - 25M
5
SignalPath's Competitor - MasterControl logo

David Edwards

CEO

82/100
500 - 1,000
$155M
$100M - 500M

SignalPath VS OpenClinica

OpenClinica is SignalPath's biggest rival. OpenClinica was founded in 2006, and is headquartered in Needham, Massachusetts. Like SignalPath, OpenClinica also works within the Health Care Equipment & Services sector. OpenClinica generates $3.6M less revenue vs. SignalPath.

SignalPath VS Clinical Ink

Clinical Ink is one of SignalPath's top competitors. Clinical Ink's headquarters is in Winston-Salem, North Carolina, and was founded in 2006. Like SignalPath, Clinical Ink also works within the Health Care Technology sector. Clinical Ink generates 200% of SignalPath's revenue.

SignalPath VS Medrio

Medrio is seen as one of SignalPath's top competitors. Medrio is a Private company that was founded in 2005 in San Francisco, California. Medrio operates in the Health Care Technology industry. Compared to SignalPath, Medrio has 100 more employees.

Frequently Asked Questions about SignalPath

  1. Who are SignalPath's top competitors?

    SignalPath's top 3 competitors are OpenClinica, Clinical Ink, Medrio.
  2. Who is similar to SignalPath?

    OpenClinica is the most similar to SignalPath. Clinical Ink and Medrio are also similar to SignalPath.
  1. Are SignalPath and OpenClinica competitors?

    Yes, OpenClinica is one of SignalPath’s top competitors.